Suchergebnisse - "Wray, Sibyl"

PubPharm (32)

1

Diroximel fumarate in patients with relapsing-remitting multiple sclerosis : Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2023

von Singer, B. | Arnold, D. | Drulovic, J. | +20

2

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

enthalten in: CNS drugs | 2023

von Jiang, T. | Ziemssen, T. | Wray, S. | +5

3

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

enthalten in: CNS drugs | 2023

von Jiang, T. | Ziemssen, T. | Wray, S. | +5

4

Satisfaction with alemtuzumab in relapsing multiple sclerosis patients : Results from the real-world PRO-ACT study

enthalten in: Multiple sclerosis journal - experimental, translational and clinical | 2022

von Wray, S. | Jacques, F. | Miller, T. | +11

5

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis

enthalten in: The New England journal of medicine | 2022

von Steinman, L. | Fox, E. | Hartung, H. | +118

6

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA) : a randomised, controlled, open-label, phase 3b trial

enthalten in: The Lancet. Neurology | 2022

von Foley, J. | Defer, G. | Ryerson, L. | +98

CommentIn: Lancet Neurol. 2022 Jul;21(7):579-581. - PMID 35483388

7

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF : Results from the Phase 3 EVOLVE-MS-1 Study

enthalten in: Advances in therapy | 2022

von Wray, S. | Then Bergh, F. | Wundes, A. | +14

8

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

enthalten in: Advances in therapy | 2022

von Wray, S. | Then Bergh, F. | Wundes, A. | +14

9

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

enthalten in: Advances in therapy | 2022

von Wray, S. | Then Bergh, F. | Wundes, A. | +14

10

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

enthalten in: Advances in therapy | 2022

von Wray, S. | Then Bergh, F. | Wundes, A. | +14